Methylene Blue Dosage: Clinical Doses and the Interaction That Matters

Methylene blue is not a peptide and not a supplement — it is an approved drug with genuine clinical indications, and it carries a drug interaction serious enough to have generated its own case-report literature. That interaction is the reason this page leads with safety rather than dosing.

The approved use

Methylene blue is approved for acquired methaemoglobinaemia — a condition in which haemoglobin is oxidised into a form that cannot carry oxygen. It reverses this reliably, which is why it is a hospital pharmacy staple.

Note that every established use is intravenous and supervised. The oral drops, gummies and tablets sold online are a different product category with no approved indication and no established dose.

The serotonergic interaction

Methylene blue is a potent monoamine oxidase inhibitor. This is the fact that most consumer sources omit, and it is the one that matters most.

Combining an MAO inhibitor with a serotonergic drug can precipitate serotonin toxicity. The case literature is specific: severe serotonin toxicity associated with methylene blue has been documented, and a 2025 cross-sectional study examined how frequently patients exposed to perioperative methylene blue were also taking serotonergic drugs — which is the scale of the problem rather than a single case.

Serotonin toxicity presents with agitation, confusion, tremor, clonus, hyperreflexia, sweating and hyperthermia, and severe cases are life-threatening. It is a medical emergency.

G6PD deficiency

Methylene blue can cause haemolysis in people with glucose-6-phosphate dehydrogenase deficiency — and in that population it is also ineffective for methaemoglobinaemia, because its mechanism depends on the enzyme pathway that is missing.

G6PD deficiency is common in people of African, Mediterranean, Middle Eastern and South-East Asian ancestry, and many people who have it do not know. It is testable.

Dose-dependent paradox

At therapeutic doses methylene blue reduces methaemoglobin. At high doses it causes it. The reversal happens within the same drug at different exposures, which is a genuine pharmacological property rather than a theoretical concern — and it is why total exposure is capped in clinical protocols.

Other effects

• Blue-green urine and stool. Expected and harmless, and often mistaken for something meaningful.

• Blue discolouration of skin and mucous membranes at higher exposures.

• Interference with pulse oximetry, producing falsely low readings — clinically relevant.

• Nausea, abdominal pain, dizziness.

• Staining of teeth and tissue with oral use.

The nootropic and mitochondrial claims

Interest in low-dose methylene blue centres on mitochondrial electron transport — it can act as an alternative electron carrier, which is a real and interesting mechanism with preclinical support.

The human evidence for cognitive or energy benefit in healthy people is thin, and the MAO inhibition is present at any dose that would plausibly do anything. The mechanism being interesting does not resolve the interaction question.

See the methylene blue guide for the wider picture and the peptides for energy guide for how these mitochondrial claims are usually constructed.

Purity matters more here than usual

Methylene blue is sold in industrial and aquarium grades that are not manufactured to pharmaceutical purity and may contain heavy metal contaminants. Pharmaceutical-grade material is a specific, verifiable thing.

The licensed vs certified guide covers how to read grade claims, and the testing labs guide covers independent verification.